Covid-19: Why patent bundling makes more sense than ever

22 May 2020

Nicholas Jones and Helen Henderson from intellectual property firm, Withers & Rogers, provide an Expert View on how patent bundling could bring unexpected rewards for innovators.

The practice of patent bundling, where companies group patent rights relating to a given research and development (R&D) project, can help facilitate licensing deals or a potential sale, and thereby bring significant rewards.

Equally, it is possible that, rather than diluting their rights and weakening their commercial potential, using intellectual property (IP) assets as a basis for strategic collaborations can accelerate development and create market opportunities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK